Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous infusion vs intermittent bolus meropenem in septic patients with increased renal function
jRCT1031240434Not yet recruiting
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of meropenem in sepsis and septic shock (2 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Achievement of PK/PD targets (50%T>MIC or 100%T>MIC). Planned start Oct 2024; status: not yet recruiting.
02
Drugs
meropenem
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on jRCT1031240434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240434.